A&P Inphatec, LLC
A&P Inphatec, LLC is commercializing the first EPA-registered product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source of the problem – giving wine growers an organic and sustainable solution to a rising threat in California. Our goal is to harness the power of bacteriophages to improve “One Health”: humans, animals, and our environment.
At A&P Inphatec, everyone has a voice, data wins arguments, and individuals are empowered to think creatively. We believe we are all on the same team working together towards a common goal. If one of us succeeds, we all succeed.
Makoto Matsumoto, Ph.D
President & CEO
Makoto Matsumoto, Ph.D. is a Otsuka senior director in the Pharmaceutical Business Division, recognized for his significant contributions to the development of anti-tuberculosis agents and treatments for kidney diseases.
In 2018, leveraging his extensive experience and expertise, Matsumoto co-founded A&P Inphatec. The company focuses on innovative bacteriophage technology to address plant diseases. Under his leadership, A&P Inphatec developed XylPhi-PD™, the world’s first effective treatment for Pierce’s Disease in grapevines, which has been approved by the US Environmental Protection Agency (EPA) and the California Department of Pesticide Regulation (CDPR). His work continues to positively impact agriculture, the environment, and health sectors.